Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib versus imatinib with switch to nilotinib in newly diagnosed chronic-phase chronic myeloid leukemia
NL-OMON60728Phase 4Completed
- Sponsor
- GIMEMA
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nilotinib, imatinib in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Started Dec 2018; status: completed.
02
Drugs
nilotinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON60728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60728.